Incidence of Recurrent Invasive Pneumococcal Disease in Canada - Scorecard - MDSpire

Incidence of Recurrent Invasive Pneumococcal Disease in Canada

  • By

  • Leah J. Ricketson

  • Altynay Shigayeva

  • Irina Rajakumar

  • Zoe Zhong

  • Kazi Hassan

  • Irene Martin

  • Alyssa Golden

  • Allison J. McGeer

  • James D. Kellner

  • Calgary Area Epidemiology Research Group and the Toronto Invasive Bacterial Diseases Network

  • Chingiz Amirov

  • Neil Rau

  • Danny Chen

  • Jeff Powis

  • Amna Faheem

  • Kevin Katz

  • Valerie Sales

  • Samir Patel

  • Abdelbaset Belhaj

  • Reena Lovinsky

  • David Rose

  • Christie Vermeiren

  • Tony Mazzulli

  • Jennie Johnstone

  • Karen Green

  • Michael Lingley

  • Andrew Simor

  • Samira Mubareka

  • Sigmund Krajden

  • Larissa Matukas

  • Sharon Walmsley

  • Medina Saffie

  • Daniel Ricciuto

  • Krystyna Ostrowska

  • David Richardson

  • Shannon N Pyra

  • Joslyn D Gray

  • July 7, 2026

  • 0 min

Share

Clinical Scorecard: Prevalence of Recurrent Invasive Pneumococcal Disease Across Canada

At a Glance

CategoryDetail
ConditionRecurrent Invasive Pneumococcal Disease (rIPD)
Key MechanismsInvasive pneumococcal disease (IPD) can lead to complications and sequelae, including increased frailty and cognitive decline. rIPD is defined as a new episode of IPD occurring more than 30 days after an initial episode.
Target PopulationAdults aged ≥18 years with a history of primary IPD.
Care SettingPopulation-based surveillance in Toronto-Peel region and Calgary Health Zone.

Key Highlights

  • rIPD occurs in 2.2% to 5.3% of individuals with IPD.
  • The incidence of rIPD is estimated to be 27 times that of primary IPD.
  • Immunocompromising conditions are known risk factors for rIPD.
  • Current guidelines do not consider prior IPD as an indication for vaccination.
  • Publicly funded vaccination programs have evolved to include newer pneumococcal conjugate vaccines.

Guideline-Based Recommendations

Diagnosis

  • IPD is defined as an acute systemic illness with S pneumoniae isolated from a normally sterile site.

Management

  • Vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) recommended for adults older than 65 years and those aged 18 to 64 years at increased risk of IPD.

Monitoring & Follow-up

  • Ongoing surveillance for IPD and rIPD is conducted in defined populations.

Risks

  • Immunocompromising conditions increase the risk of rIPD.

Patient & Prescribing Data

Adults aged ≥18 years who survived a primary episode of IPD.

Vaccination history is critical for understanding risk and recurrence.

Clinical Best Practices

  • Conduct active population-based surveillance for IPD.
  • Utilize appropriate serotyping methods for S pneumoniae isolates.
  • Assess patient characteristics and comorbidities at the time of primary IPD episode.

Related Resources & Content

Original Source(s)

Incidence of Recurrent Invasive Pneumococcal Disease in Canada

  • by Leah J. Ricketson, Altynay Shigayeva, Irina Rajakumar, Zoe Zhong, Kazi Hassan, Irene Martin, Alyssa Golden, Allison J. McGeer, James D. Kellner, Calgary Area Epidemiology Research Group and the Toronto Invasive Bacterial Diseases Network, Chingiz Amirov, Neil Rau, Danny Chen, Jeff Powis, Amna Faheem, Kevin Katz, Valerie Sales, Samir Patel, Abdelbaset Belhaj, Reena Lovinsky, David Rose, Christie Vermeiren, Tony Mazzulli, Jennie Johnstone, Karen Green, Michael Lingley, Andrew Simor, Samira Mubareka, Sigmund Krajden, Larissa Matukas, Sharon Walmsley, Medina Saffie, Daniel Ricciuto, Krystyna Ostrowska, David Richardson, Shannon N Pyra, Joslyn D Gray

  • July 7, 2026

Related Content

Association between perfluoroalkyl and polyfluoroalkyl substances and response to the COVID-19 vaccine in a paediatric prospective observational cohort in Arizona

Evaluation of a strain Long human respiratory syncytial virus with M2–2 gene deletion in intranasally vaccinated BALB/c mice

Poll: People Without a Trusted Health Care Provider Are More Likely to Endorse Vaccine Myths, As Are Those Who Often Use Social Media or AI for Health Information